Treeway
Treeway is a Netherlands-based clinical-stage biotechnology company developing oral edaravone (TW001) and other therapies for ALS and Alzheimer's disease, monetizing through regional licensing partnerships and non-dilutive grants rather than direct commercialization.
- Company typePrivate
- Founded2012
- HeadquartersRotterdam, Netherlands
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Treeway does
Treeway B.V. is a privately held, clinical-stage biotechnology company founded in 2012 in Tilburg, the Netherlands, by two ALS patients, Bernard Muller and Robbert Jan Stuit, with the mission of developing disease-modifying therapies for ALS, Alzheimer's disease, and other neurodegenerative conditions. The company's lead asset, TW001 (also known as FNP122), is a patented oral formulation of the free-radical scavenger edaravone designed to improve bioavailability and patient convenience over the intravenous reference product Radicava. The pipeline also includes TW002, a combination therapy for Alzheimer's disease, and preclinical programs targeting new ALS pathways, supported by biomarker and genetics research collaborations with academic centers including ALS Centrum Nederland, Alzheimer Center Amsterdam, and TRICALS. Treeway holds Orphan Drug Designations for TW001 from both the EMA (2014) and the FDA (2015).
Operationally, Treeway runs a minimalist organization of 1-10 employees and a lean management team led by CEO Inez de Greef, supported by a Scientific Advisory Board that includes Prof. Philip Scheltens and Prof. Leonard van den Berg. The company does not commercialize products directly; instead, it pursues an asset-out licensing model. TW001/FNP122 was licensed to Ferrer for ALS development and commercialization in Europe and select Asian markets in October 2021, and to Specialised Therapeutics Asia for Australia and New Zealand in August 2023. R&D is co-funded by non-dilutive grants from the US Department of Defense, the Dutch Ministry of Economic Affairs' Innovation Credit, and the Alzheimer Drug Discovery Foundation. The Phase 3 ADORE trial for ALS failed to meet its primary endpoints in January 2024, but the Phase 2a ASURE trial in mild-to-moderate Alzheimer's disease completed enrollment in September 2024, with results accepted for late-breaking presentation at the CTAD 2025 conference.
Treeway firmographics
Firmographics- Name
- Treeway
- Legal name
- Treeway B.V.
- Website
- https://treeway.nl
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Treeway is a Netherlands-based clinical-stage biotechnology company developing oral edaravone (TW001) and other therapies for ALS and Alzheimer's disease, monetizing through regional licensing partnerships and non-dilutive grants rather than direct commercialization.
- Ownership category
- akta.pro rank
Treeway industry classification
Industry- Product category
- Clinical-Stage Biotechnology (Neurodegenerative Disease Therapeutics)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where Treeway is headquartered
LocationHeadquarters
- HQ city
- Rotterdam
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
Treeway business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Licensing Royalties: Treeway licenses its drug candidates to pharmaceutical partners for development and commercialization. Under the Ferrer agreement, Ferrer is responsible for advancing development and commercialization and makes royalty payments to Treeway at certain milestones. Similar arrangement with Specialised Therapeutics for Australia/New Zealand.
- Grant Funding: Treeway's development programs are co-funded by external organizations including the Alzheimer Drug Discovery Foundation (ADDF), the United States Department of Defense (DoD), and The Dutch Ministry of Economic Affairs' Innovation Credit.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Treeway product offering
Product offeringCore offering
Treeway is a clinical-stage biotechnology company developing drug therapies for neurodegenerative diseases, with lead candidate TW001 (an oral formulation of edaravone) being progressed in a Phase 2a ASURE trial for Alzheimer's disease following a completed Phase 3 ADORE study in ALS, and a second candidate TW002 in earlier-stage development. The company advances candidates through clinical development and out-licenses regional commercialization rights to pharmaceutical partners such as Ferrer (Europe, parts of Asia) and Specialised Therapeutics (Australia, New Zealand) in exchange for milestone payments and royalties. Development is co-funded by grants from the US Department of Defense, the Dutch Ministry of Economic Affairs' Innovation Credit, and the Alzheimer's Drug Discovery Foundation.
Product overview
Treeway is a clinical-stage biotechnology company developing drug therapies for neurodegenerative diseases, particularly ALS and Alzheimer's disease. The company's pipeline consists of two main drug products: TW001 (lead product, oral edaravone formulation) and TW002. TW001 is being developed for both ALS and Alzheimer's disease, having received Orphan Drug Designation from both EMA (2014) and FDA (2015). Discovery programs include biomarkers and genetics, motor neuron signaling, and immune system research.
Differentiator
Problem solved
Functional benefit
Brands
- TW001: Oral edaravone formulation - Treeway's lead product targeting oxidative stress for ALS and Alzheimer's disease treatment.
- FNP122
- ASURE
- ADORE
Products and services
- TW001 (Oral Edaravone) TW001 is Treeway's lead investigational product: a patented, patient-friendly oral formulation of the free radical scavenger edaravone, developed as a disease-modifying therapy targeting oxidative stress in ALS and Alzheimer's disease. It is designed for daily oral dosing to replace or complement existing intravenous edaravone (Radicava) therapy, with improved bioavailability demonstrated in Phase 1 and clinical evaluation ongoing in the Phase 2a ASURE study for Alzheimer's disease (and previously in the Phase 3 ADORE study for ALS). The product is out-licensed to Ferrer (as FNP122) for Europe and selected Asian countries and to Specialised Therapeutics for Australia and New Zealand.
- TW002 TW002 is the second drug candidate in Treeway's pipeline for neurodegenerative diseases, currently in preclinical/early development. It is referenced alongside TW001 as part of Treeway's broader effort to develop disease-modifying therapies for ALS and other neurodegenerative indications.
Quantifiable outcome
- Oral formulation bioavailability exceeded that of intravenous Radicava infusion in Phase 1 study
- +2 more outcomes
Companies that use Treeway
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Treeway technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Treeway partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Specialised Therapeutics AsiacoreLicensing partnership to commercialise TW001 for ALS/MND in Australia and New Zealand. ST is an international biopharmaceutical company headquartered in Singapore, responsible for all marketing, regulatory and distribution activities in the region. This is ST's first CNS therapy in their portfolio.
- FerrercoreLicensing agreement for development and commercialisation of oral edaravone (TW001/FNP122) for Amyotrophic Lateral Sclerosis in certain territories including Europe and some Asian countries. Ferrer is responsible for advancing development and commercialisation and will make royalty payments to Treeway at certain milestones. Ferrer is an international pharmaceutical company focused on neurological disorders and pulmonary vascular diseases.
- 3D-PharmXchangeminorDrug development partner and pharmaceutical consultancy company founded by Treeway co-founders Inez de Greef and Ronald van der Geest. Provides fit-for-purpose drug development solutions to clients in pharma, biotech and healthcare companies with long-standing experience in managing multi-disciplinary projects.
- ALS Centrum NederlandcoreThe ALS Center in The Netherlands is led by director Dr. Leonard H. van den Berg and provides diagnosis, care and treatment for ALS patients. Part of the University Medical Center (UMC) in Utrecht. Treeway collaborates for biomarker and genetic research.
- Alzheimer center AmsterdamcorePart of Amsterdam UMC specializing in Alzheimer and dementia research. Over 100 employees provide diagnosis and treatment. Director Philip Scheltens is one of the top ten most cited scientists in Alzheimer research. Treeway collaborates to evaluate potential treatments and research the neurodegenerative disease.
- TRICALScoreTreatment Research Institute for the Cure of ALS is an international online platform for people with ALS. Treeway actively collaborates with TRICALS to accelerate clinical research to ultimately find effective treatment for ALS. Supported the ADORE Phase III clinical trial.
- Project MinEminorLargest ALS research consortium devoted to discovering the genetic make-up for ALS. Initiated by Treeway founders Bernard Muller and Robbert Jan Stuit. Goal is to identify genes associated with ALS whose function may lead to disease pathways.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Treeway competitors and assessment
Company assessmentDirect peers
- Cytokinetics: Cytokinetics is a clinical-stage biopharmaceutical company focused on developing muscle activators for ALS and other neuromuscular diseases. It is a direct peer given Treeway's overlapping ALS focus and shared reliance on ALS patient community engagement and Phase 3 clinical execution.
- Anavex Life Sciences: Anavex is a clinical-stage biotechnology company developing small-molecule therapeutics for Alzheimer's disease, Rett syndrome, and other neurodegenerative indications. It is comparable to Treeway given the shared focus on orally bioavailable small molecules targeting CNS/neurodegenerative diseases at similar clinical-stage maturity.
- Prothena Corporation: Prothena is a clinical-stage biotech developing protein-immunomodulatory therapies for neurodegenerative diseases including Alzheimer's and Parkinson's. It is a direct peer to Treeway given overlapping neurodegenerative pipeline focus, clinical-stage development, and reliance on similar academic and big-pharma partnership models.
- AB Science: AB Science is a clinical-stage pharmaceutical company developing tyrosine kinase inhibitors, including masitinib for ALS. It is a direct peer to Treeway given the shared ALS indication focus, small-molecule approach, and similar clinical-stage development of disease-modifying therapies for a rare neurodegenerative indication.
- Ionis Pharmaceuticals: Ionis is a clinical- and commercial-stage antisense oligonucleotide developer with programs in ALS (e.g., tofersen collaboration with Biogen) and other neurological disorders. It is a direct peer given the shared ALS development focus, comparable clinical-stage programs, and CNS drug-development orientation.
Emerging players
- Denali Therapeutics: Denali Therapeutics is a clinical-stage biotech developing therapeutics for neurodegenerative diseases including Parkinson's, ALS, and Alzheimer's, using a targeted degradation and blood-brain barrier delivery platform. It is an emerging player comparable to Treeway given shared neurodegenerative focus and clinical-stage maturity, though Denali operates with broader indications and a larger platform.
- AZTherapies: AZTherapies is a clinical-stage biotechnology company developing small-molecule therapeutics for neurodegenerative diseases including Alzheimer's. It is an emerging player comparable to Treeway given the similar focus on orally administered disease-modifying small molecules for neurodegenerative indications.
Broad incumbents
- Biogen: Biogen is a major global biopharmaceutical company with a broad neurodegenerative disease franchise including Qalsody for ALS and Aduhelm/lecanemab in Alzheimer's. It is a broad incumbent peer given its established leadership in the same neurodegenerative indications where Treeway operates and its role as a potential licensing/acquisition counterparty.
- Eisai: Eisai is a major global pharmaceutical company with a leading Alzheimer's franchise (lecanemab, in partnership with Biogen) and CNS development capabilities. It is a broad incumbent peer given its established position in the Alzheimer's market where Treeway's TW001 oral edaravone would compete.
Regional players
- reMYND: reMYND is a Belgium-based clinical-stage biotech developing therapeutics targeting neurodegenerative diseases, particularly Alzheimer's and Parkinson's. It is a regional player comparable to Treeway given shared European base, similar clinical-stage maturity, and overlapping neurodegenerative disease focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Treeway social profiles
Digital presenceTreeway compliance and trust
Trust signalCompliance2 records
Treeway financial estimates
Financial estimateRevenue estimate
Valuation estimate
Treeway leadership team
Management profileNumber of profiles
Profiles10 records
Treeway funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Treeway M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Treeway
What does Treeway do?
Treeway is a clinical-stage biotechnology company developing drug therapies for neurodegenerative diseases, with lead candidate TW001 (an oral formulation of edaravone) being progressed in a Phase 2a ASURE trial for Alzheimer's disease following a completed Phase 3 ADORE study in ALS, and a second candidate TW002 in earlier-stage development. The company advances candidates through clinical development and out-licenses regional commercialization rights to pharmaceutical partners such as Ferrer (Europe, parts of Asia) and Specialised Therapeutics (Australia, New Zealand) in exchange for milestone payments and royalties. Development is co-funded by grants from the US Department of Defense, the Dutch Ministry of Economic Affairs' Innovation Credit, and the Alzheimer's Drug Discovery Foundation.
Is Treeway a public or private company?
Treeway is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Treeway founded?
Treeway was founded in 2012. It employs 1 to 10 people.
Where is Treeway based?
Treeway is headquartered in Rotterdam, Netherlands, in the Europe region.
How does Treeway make money?
Two revenue lines are on record. Licensing Royalties are the primary driver. The others are grant Funding.
Who are Treeway's main competitors?
Direct peers on record are Cytokinetics, Anavex Life Sciences, Prothena Corporation, AB Science and Ionis Pharmaceuticals. Emerging players are Denali Therapeutics and AZTherapies. Broad incumbents are Biogen and Eisai. reMYND is listed as a regional player.
Does Treeway have an API?
No public API is recorded for Treeway.
What industry is Treeway in?
Treeway's product category is Clinical-Stage Biotechnology (Neurodegenerative Disease Therapeutics). Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 541714 and its SIC code is 2834.